Longer bouts of exercise may be associated with decreased mortality and cardiovascular disease
1. In this prospective cohort study, cumulative all-cause mortality and risk for cardiovascular disease were lower among adults who accumulated ...
Tag: cardiovascular mortality
“Weekend warrior” and regular physical activity patterns may both reduce cardiovascular and all-cause mortality
1. In this prospective cohort study of adults with diabetes, “weekend warrior” and regular physical activity patterns were associated with ...
Hemodynamic monitoring improves quality of life and reduces hospitalizations in heart failure patients
1. Patients assigned to hemodynamic monitoring reported improved quality of life than those receiving contemporary guideline-directed medical therapy. 2. The ...
C-reactive protein may have superior prognostic value compared to low-density lipoprotein cholesterol for patients on statin therapy
1. High-sensitivity C-reactive protein increased the risk of all-cause mortality by two- to three-fold among all three randomized trials. 2. ...
Empagliflozin use is associated with slower progression of chronic kidney disease
1. Empagliflozin led to a lower risk of kidney disease progression in patients with chronic kidney disease (CKD) as compared ...
Bivalirudin during and post-percutaneous coronary intervention reduces bleeding and mortality compared to heparin monotherapy
1. Bivalirudin during percutaneous coronary intervention plus high-dose infusion after demonstrated decreased all-cause mortality compared to heparin monotherapy. 2. Risk ...
Allopurinol does not reduce cardiovascular risk for patients with ischemic heart disease without gout
1. The composite score for non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death was comparable between allopurinol (11.0%) and usual ...
Beneficial effect of intensive blood pressure control on cardiovascular and all-cause mortality not persist after trial intervention – a secondary analysis of the SPRINT trial
1. Intensive blood pressure control regime was associated with improved cardiovascular and all-cause mortality at a median follow-up point of ...
Dapagliflozin associated with reduction in cardiovascular mortality due to lower rates of death from heart failure and sudden death – Pooled analysis of DAPA-HF and DELIVER
1. In this pooled analysis of 11,007 patients with heart failure in the DAPA-HF and DELIVER trials, treatment with dapagliflozin ...
SGLT-2 inhibitors provide morbidity and mortality benefits for patients with heart failure
1. SGLT-2 inhibitors reduced time to first hospitalization and cardiovascular death among patients with preserved, mildly reduced, and reduced ejection ...
